LONDON & CARLSBAD, Calif., October 27, 2021--(BUSINESS WIRE)--Together with Imperial College London (‘Imperial’), DNAe has been awarded a UK Knowledge Transfer Partnership (KTP) by Innovate UK to support development of its next generation sequencing (NGS)-based diagnostic platform for use in cancer monitoring.
The KTP program connects innovative businesses with academic experts who can help them deliver their ideas. This award formalizes a collaboration between DNAe and Professor Charles Coombes, Professor of Medical Oncology at Imperial. The work of the KTP will build on the existing research partnership between Professor Coombes and Professor Jacqui Shaw, Head of the Department of Genetics and Genome Biology and Professor of Translational Cancer Genetics at the University of Leicester.
The aim of the program is to develop a ‘liquid biopsy’ test based on DNAe’s proprietary "sample to answer" NGS technology, to directly detect and identify biomarkers and mutation hotspots that have been identified in Professors Coombes’ and Shaw’s research. This will enable these markers to be used to monitor treatment and detect early recurrence of breast cancer. Under the terms of the partnership, a post graduate researcher (the KTP Associate) will be based at DNAe to integrate expertise from the academic partners into the development of the test.
Samuel Reed, CEO of DNAe, said: "Recognizing that October is Breast Cancer Awareness Month, we’re delighted to formally announce our collaboration with world experts Professors Coombes and Shaw who bring their extensive knowledge of using circulating tumor DNA to manage the treatment of breast cancers. Through this KTP award, we will be able to harness that deep expertise and combine it with our proven diagnostic technology. Together, we aim to develop a liquid biopsy platform that can deliver accurate and timely results for clinicians and their patients, providing the opportunity for early intervention and much-needed peace of mind."
DNAe’s integrated, sequencing-based technology will bring genomic analysis to the point-of-need, enabling testing to move out of specialist laboratories and closer to the patient. By detecting and sequencing tumor DNA directly from raw blood samples in a matter of hours, DNAe’s platform has the potential to expose unresponsive or recurrent cancer earlier. This approach will enable clinicians to make timely treatment decisions rather than waiting days or weeks for sequencing results.
Professor Charles Coombes, Professor of Medical Oncology, Imperial, and Honorary Consultant Medical Oncologist, Imperial College Healthcare Trust, said: "Cancer monitoring is a vital component of successful treatment. Firstly, we need to ensure a patient’s tumor is responding to the therapy, and secondly, patients in remission must be monitored for signs of recurrence. The current monitoring options are slow, and any delays to appropriate cancer care can lower the chance of survival and increase treatment-associated problems and costs. Although we are at the early stages, I believe that DNAe’s integrated, sequencing-based platform could ultimately provide rapid, actionable information that saves patients’ lives."
Professor Jacqui Shaw, Head of the Department of genetics and genome Biology, University of Leicester, added: "This is an exciting collaboration with DNAe and Imperial, where we will combine our expertise to develop a rapid integrated liquid biopsy platform for management of patients with breast cancer."
- ENDS -
For more information, visit: www.dnae.com
About Imperial College London
For more information, visit: http://www.imperial.ac.uk/
About University of Leicester
For more information, visit: https://le.ac.uk/about
View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005063/en/
Samuel Reed, President, DNAe Group
Please contact me via Instinctif (see below)
Instinctif Partners (media relations)
Tel: +44 (0) 20 7457 2040
Tim Watson / Katie Duffell / Grace Rutter